Stay updated on Bristol Myers Squibb Press Releases

Sign up to get notified when there's something new on the Bristol Myers Squibb Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Bristol Myers Squibb Press Releases page

  1. Check
    yesterday
    Change Detected
    Summary
    The release list now features two newer announcements covering an R&D organization update and 56-week Phase 3 data for Camzyos in pediatric patients. Older releases about multiple myeloma results and a healthcare-professional initiative no longer appear in the listing.
    Difference
    6%
    Check dated 2026-11-12T18:24:44.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    The release feed has been refreshed with late-October announcements, including Bristol Myers Squibb’s third-quarter 2026 results and new oncology and multiple-sclerosis study findings. Several September announcements, including an FDA indication expansion and a dividend notice, are no longer in the displayed list.
    Difference
    6%
    Check dated 2026-10-29T19:10:27.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    A new October 19, 2026, press release announces Bristol Myers Squibb’s planned showcase of next-generation cancer modalities and solid-tumor leadership at ESMO 2026. The listing no longer includes the September 8, 2026, release about positive Phase 2 QUINTESSENTIAL trial results for arlocabtagene autoleucel.
    Difference
    5%
    Check dated 2026-10-22T20:12:19.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The press release listing now features two October 12, 2026 announcements reporting Phase 3 trial results for RYZ101 and admilparant. Earlier August 2026 announcements about Camzyos and ZENBEXUS are no longer listed.
    Difference
    6%
    Check dated 2026-10-15T20:31:11.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The press-release listing adds an October 8 announcement that ZENBEXUS with daratumumab and dexamethasone demonstrated superior progression-free survival in a Phase 3 multiple myeloma trial. It no longer lists the August 10 announcement of Bristol Myers Squibb’s planned $2.3 billion manufacturing campus in Houston.
    Difference
    6%
    Check dated 2026-10-08T20:36:41.000Z thumbnail image
  7. Check
    43 days ago
    Change Detected
    Summary
    New press releases were added for October 1, 2026; September 30, 2026; and September 25, 2026, expanding the current lineup of company announcements. Older items from July 2026 were removed from the listing, updating the archive content on the press releases page.
    Difference
    7%
    Check dated 2026-10-01T19:23:17.000Z thumbnail image

Stay in the know with updates to Bristol Myers Squibb Press Releases

Enter your email address, and we'll notify you when there's something new on the Bristol Myers Squibb Press Releases page.